Weekly Spotlight - 19.12.24

In the news

Higher MTX-PG Levels Boost RA Treatment but Pose Liver Risks

Higher methotrexate-polyglutamate levels improve rheumatoid arthritis treatment but increase liver risk. The study shows better outcomes initially, yet risks persist. Patients with low weight, albumin, or kidney issues need careful monitoring. Regular checks are vital for safety. The research highlights the balance between efficacy and potential harm.

Medication-Assisted Weight Loss Transforms Lives in Rheumatic Disease Management

Medication-assisted weight loss, including GLP-1 agonists and surgery, improves outcomes in rheumatic diseases. Patients achieving 5% weight loss report better pain and fatigue management. This promising approach benefits those with obesity, regardless of their condition, suggesting potential for targeted trials to enhance patient care and disease management.

Rheumatoid Arthritis Breakthroughs: Hopeful Advances from ACR Convergence 2024

Dr Ambreesh Chawla summarised key rheumatoid arthritis studies from ACR Convergence 2024. Important trials like APIPPRA, ARIAA, and MIRACLE were discussed, focusing on preventing rheumatoid arthritis in high-risk individuals. The SAIL-RA trial was also highlighted, offering hope and insights for future treatment strategies.

Cancer Risk in RA: Understanding Rituximab and Abatacept Impact

Rituximab and abatacept, used for rheumatoid arthritis, may increase cancer risk within two years of treatment. A study found these drugs linked to higher cancer rates compared to TNF inhibitors. Larger studies are needed to confirm these findings and ensure patient safety.